AT-001

Unassigned

New Medicines

Diabetic cardiomyopathy

Information

New molecular entity
Applied Therapeutics
Applied Therapeutics

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Selective aldose reductase inhibitor
Diabetic cardiomyopathy affects 17 – 24 percent of those with both types of diabetes and is a rapidly progressing degenerative disorder of the heart. It affects approximately 77 million patients worldwide [1].
Diabetic cardiomyopathy
Oral

Trial or other data

Oct 19 · PIII ARISE-HF (NCT04083339) trial is recruiting, with an estimated primary completion date of Sept 2021 [2].
Sep 19 · PIII registrational trial starts for AT-001, a potent and selective aldose reductase inhibitor (ARI). ARISE-HF will investigate its effect on the decline of functional capacity in patients with diabetic cardiomyopathy at high risk of progression to overt heart failure [1]